-
1
-
-
76649095097
-
-
WHO. (2009) Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. Accessed July 1, 2009, at: http://www.who.int/csr/ disease/avian influenza/country/ cases table 2009 07 01/en/index.html.
-
WHO. (2009) Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. Accessed July 1, 2009, at: http://www.who.int/csr/ disease/avian influenza/country/ cases table 2009 07 01/en/index.html.
-
-
-
-
2
-
-
76649101225
-
-
vaccine viruses developed for potential use as pre-pandemic Vaccines. Accessed July 18, at
-
WHO. (2009) Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic Vaccines. Accessed July 18, 2009, at: http://www.who.int/csr/disease/avian influenza/guidelines/ 200902 H5VaccineVirusUpdate.pdf.
-
(2009)
Antigenic and genetic characteristics of H5N1 viruses and candidate
, Issue.N1
-
-
-
3
-
-
76649103851
-
-
WHO. (2007) Tables on the Clinical trials of pandemic influenza prototype vaccines. WHO meeting Available at: http://www.who.int/vaccine.research/ diseases/influenza/ flu trials tables/en/index3.html.
-
WHO. (2007) Tables on the Clinical trials of pandemic influenza prototype vaccines. WHO meeting Available at: http://www.who.int/vaccine.research/ diseases/influenza/ flu trials tables/en/index3.html.
-
-
-
-
4
-
-
76649103543
-
-
Tashiro M. (2003) Safety and efficacy of an inactivated whole-virion influenza A (H5N1) vaccine. MHLW Res: 200201019A (Japanese language only).
-
Tashiro M. (2003) Safety and efficacy of an inactivated whole-virion influenza A (H5N1) vaccine. MHLW Res: 200201019A (Japanese language only).
-
-
-
-
5
-
-
2442597735
-
Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use
-
Hehme N., Engelmann H., KuenzelW., Neumeier E., Saenger R. (2004) Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103: 163-71.
-
(2004)
Virus Res
, vol.103
, pp. 163-171
-
-
Hehme, N.1
Engelmann, H.2
KuenzelW3
Neumeier, E.4
Saenger, R.5
-
6
-
-
0036458071
-
Pandemic preparedness: Lessons learnt from H2N2 and H9N2 candidate vaccines
-
Hehme N., Engelmann H., KunzelW., Neumeier E., Sanger R. (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191: 203-8.
-
(2002)
Med Microbiol Immunol
, vol.191
, pp. 203-208
-
-
Hehme, N.1
Engelmann, H.2
KunzelW3
Neumeier, E.4
Sanger, R.5
-
7
-
-
34147181229
-
Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
-
Ninomiya A., Imai M., Tashiro M., Odagiri T. (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25: 3554-60.
-
(2007)
Vaccine
, vol.25
, pp. 3554-3560
-
-
Ninomiya, A.1
Imai, M.2
Tashiro, M.3
Odagiri, T.4
-
8
-
-
33344466421
-
Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults
-
Cook I.F., Barr I., Hartel G., Pond D., Hampson A.W. (2006) Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 24: 2395-402.
-
(2006)
Vaccine
, vol.24
, pp. 2395-2402
-
-
Cook, I.F.1
Barr, I.2
Hartel, G.3
Pond, D.4
Hampson, A.W.5
-
9
-
-
76649112893
-
-
American Academy of Pediatrics. (1997) RED BOOK, 24th Edition (ISBN: 0-910761-85-x). p14.
-
American Academy of Pediatrics. (1997) RED BOOK, 24th Edition (ISBN: 0-910761-85-x). p14.
-
-
-
-
10
-
-
2442599892
-
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine
-
Stephenson I.,Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-5.
-
(2004)
Virus Res
, vol.103
, pp. 91-95
-
-
Stephenson, I.1
Wood, J.M.2
Nicholson, K.G.3
Charlett, A.4
Zambon, M.C.5
-
11
-
-
76649090445
-
Committee for Proprietary Medicinal Products (CPMP)
-
European Medicine Agency, CPMP/BWP/214/96, Available at
-
European Medicine Agency. (1997) Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). Available at: http://www.emea.europa.eu/ pdfs/human/ bwp/021496en.pdf.
-
(1997)
Note for guidance on harmonization of requirements for influenza vaccines
-
-
-
12
-
-
33748447102
-
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised controlled trial
-
YinW
-
Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y.,Wang Z., Yang M., Sun R., Li C., Lin S., Ji M., Liu Y.,Wang X.,Wood J., Feng Z.,Wang Y., YinW. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991-7.
-
(2006)
Lancet
, vol.368
, pp. 991-997
-
-
Lin, J.1
Zhang, J.2
Dong, X.3
Fang, H.4
Chen, J.5
Su, N.6
Gao, Q.7
Zhang, Z.8
Liu, Y.9
Wang, Z.10
Yang, M.11
Sun, R.12
Li, C.13
Lin, S.14
Ji, M.15
Liu, Y.16
Wang, X.17
Wood, J.18
Feng, Z.19
Wang, Y.20
more..
-
13
-
-
33645399959
-
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
-
Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T.,Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-51.
-
(2006)
N Engl J Med
, vol.354
, pp. 1343-1351
-
-
Treanor, J.J.1
Campbell, J.D.2
Zangwill, K.M.3
Rowe, T.4
Wolff, M.5
-
14
-
-
33646549355
-
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial
-
Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M.,Wood J., Hoschler K., Zambon M.C. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-64.
-
(2006)
Lancet
, vol.367
, pp. 1657-1664
-
-
Bresson, J.L.1
Perronne, C.2
Launay, O.3
Gerdil, C.4
Saville, M.5
Wood, J.6
Hoschler, K.7
Zambon, M.C.8
-
15
-
-
45149129921
-
-
Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-84.
-
Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Low-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pollabauer E.M., Kistner O., Barrett P.N. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358: 2573-84.
-
-
-
-
16
-
-
63649119320
-
-
Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M.,Wang N., YinW.D., Dong X.P. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: 1087-95.
-
Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., Qiu Y.Z., Liu Y., Lu M., Liu L.Y., Dong S.S., Gao Q., Zhang X.M.,Wang N., YinW.D., Dong X.P. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48: 1087-95.
-
-
-
-
17
-
-
34247275658
-
Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: An international collaborative study
-
Stephenson I., Das R.G.,Wood J.M., Katz J.M. (2007) Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25: 4056-63.
-
(2007)
Vaccine
, vol.25
, pp. 4056-4063
-
-
Stephenson, I.1
Das, R.G.2
Wood, J.M.3
Katz, J.M.4
-
18
-
-
66449095061
-
Characterization of a whole, inactivated influenza (H5N1) vaccine
-
Tada Y. (2008) Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza Other Respi Viruses 2: 261-6.
-
(2008)
Influenza Other Respi Viruses
, vol.2
, pp. 261-266
-
-
Tada, Y.1
-
19
-
-
34447544007
-
-
Kistner O., Howard M.K., Spruth M.,WodalW., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., MundtW., Falkner F.G., Barrett P.N. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-36.
-
Kistner O., Howard M.K., Spruth M.,WodalW., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., MundtW., Falkner F.G., Barrett P.N. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-36.
-
-
-
-
20
-
-
0015354129
-
A new subunit influenza vaccine: Acceptability compared with standard vaccines and effect of dose on antigenicity
-
Ruben F.L., Jackson G.G. (1972) A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis 125: 656-64.
-
(1972)
J Infect Dis
, vol.125
, pp. 656-664
-
-
Ruben, F.L.1
Jackson, G.G.2
-
21
-
-
0030581380
-
Immunogenicity and safety of a new inactivated hepatitis A vaccine: A clinical trial with comparison of administration route
-
Fisch A., Cadilhac P., Vidor E., Prazuck T., Dublanchet A., Lafaix C. (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14: 1132-6.
-
(1996)
Vaccine
, vol.14
, pp. 1132-1136
-
-
Fisch, A.1
Cadilhac, P.2
Vidor, E.3
Prazuck, T.4
Dublanchet, A.5
Lafaix, C.6
-
22
-
-
0032866083
-
Studies on a Hib-tetanus toxoid conjugate vaccine: Effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine
-
Carlsson R.M., Claesson B.A., Kayhty H., Selstam U., Iwarson S. (1999) Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine 18: 468-78.
-
(1999)
Vaccine
, vol.18
, pp. 468-478
-
-
Carlsson, R.M.1
Claesson, B.A.2
Kayhty, H.3
Selstam, U.4
Iwarson, S.5
-
23
-
-
0033537873
-
Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents
-
Mark A., Carlsson R.M., Granstrom M. (1999) Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 17: 2067-72.
-
(1999)
Vaccine
, vol.17
, pp. 2067-2072
-
-
Mark, A.1
Carlsson, R.M.2
Granstrom, M.3
-
24
-
-
9244240275
-
Serum antibody responses after intradermal vaccination against influenza
-
Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., Howe B.J., Dubin G. (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351: 2286-94.
-
(2004)
N Engl J Med
, vol.351
, pp. 2286-2294
-
-
Belshe, R.B.1
Newman, F.K.2
Cannon, J.3
Duane, C.4
Treanor, J.5
Van Hoecke, C.6
Howe, B.J.7
Dubin, G.8
-
25
-
-
76649091745
-
-
KeitelW, Available at
-
Shital Patel R.A., El-Sahly H., Cate T., KeitelW. (2007) A Randomized, Open-Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization with Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal (ID) or the Intramuscular (IM) Route Among Healthy Adults. Available at: http://www.who.int/vaccine research/diseases/ influenza/160207 keitel.pdf.
-
(2007)
A Randomized, Open-Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization with Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal (ID) or the Intramuscular (IM) Route Among Healthy Adults
-
-
Shital Patel, R.A.1
El-Sahly, H.2
Cate, T.3
-
26
-
-
47349124848
-
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults
-
Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., Hoschler K., Bennet J., Ryan D., Papanaoum K., Basser R.L., Zambon M.C. (2008) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26: 4160-7.
-
(2008)
Vaccine
, vol.26
, pp. 4160-4167
-
-
Nolan, T.M.1
Richmond, P.C.2
Skeljo, M.V.3
Pearce, G.4
Hartel, G.5
Formica, N.T.6
Hoschler, K.7
Bennet, J.8
Ryan, D.9
Papanaoum, K.10
Basser, R.L.11
Zambon, M.C.12
-
27
-
-
34547837401
-
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial
-
Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., Devaster J.M., Leroux-Roels G. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-9.
-
(2007)
Lancet
, vol.370
, pp. 580-589
-
-
Leroux-Roels, I.1
Borkowski, A.2
Vanwolleghem, T.3
Drame, M.4
Clement, F.5
Hons, E.6
Devaster, J.M.7
Leroux-Roels, G.8
-
28
-
-
0035897889
-
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza
-
Nicholson K.G., Colegate A.E., Podda A., Stephenson I.,Wood J., Ypma E., Zambon M.C. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-43.
-
(2001)
Lancet
, vol.357
, pp. 1937-1943
-
-
Nicholson, K.G.1
Colegate, A.E.2
Podda, A.3
Stephenson, I.4
Wood, J.5
Ypma, E.6
Zambon, M.C.7
|